Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04179357
Other study ID # Hemostatic Disorders
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date January 2020
Est. completion date September 2020

Study information

Verified date November 2019
Source Assiut University
Contact Mohamed Fawzi Ibrahim, Master
Phone +201099028136
Email muhammadfawzi10@gmail.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

1. To assess the incidence of hemostatic disorders among ICU patients.

2. To establish a relationship between supportive treatment and survival in patients with coagulopathy in ICU.

3. To provide solutions that can help in reduction of the incidence of hemostatic disorders in ICU patients.


Description:

Hemostasis is the physiological process that stops bleeding at the site of an injury while maintaining normal blood flow elsewhere in the circulation. Blood loss is stopped by formation of a hemostatic plug. The endothelium in blood vessels maintains an anticoagulant surface that serves to maintain blood in its fluid state, but if the blood vessel is damaged components of the subendothelial matrix are exposed to the blood. Several of these components activate the two main processes of hemostasis to initiate formation of a blood clot, composed primarily of platelets and fibrin.

Many critically ill patients develop hemostatic abnormalities, ranging from isolated thrombocytopenia to complex defects, such as DIC. Coagulation abnormalities are commonly found in critically ill patients. Prompt and proper identification of the underlying cause of these coagulation abnormalities is required, since each coagulation disorder necessitates very different therapeutic management strategies.

Management of coagulopathy The key basic management principle of all coagulopathies is that the decision to transfuse blood products should not be based on the results of coagulation tests alone, rather an individualized approach is warranted. It is imperative to synthesizes all the available clinical data and treat the underlying cause.

In summary, hemostatic disorders are very common in the critically ill. Blood product support is frequently required, but there is only a very limited evidence-base to support its use. In many cases, no specific product support is required and the key management step is the treatment of the condition underlying the coagulopathy .


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 100
Est. completion date September 2020
Est. primary completion date September 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 90 Years
Eligibility Inclusion Criteria:

- Intensive care unit patients,aged more than 18 years .

- Any Acquired bleeding disorders (platelet disorders; thrombocytopenia, acquired thrombocythemia and thrombocytosis, acquired coagulation defect, Thrombophilia ) Diagnosed in Critical care unit in Assiut university in one year time frame

Exclusion Criteria:

- Patient less than 18 years.

- Patients with Inherited platelet defects ( Amegakaryoctye aplasia and Bernard Soulir syndrome)

- Patients with Inherited coagulation defects (e.g.hemophilia , Von Willebrand disease and any inherited coagulation defect.

Study Design


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Assiut University

References & Publications (2)

Hunt BJ. Bleeding and coagulopathies in critical care. N Engl J Med. 2014 Feb 27;370(9):847-59. doi: 10.1056/NEJMra1208626. Review. — View Citation

Retter A, Barrett NA. The management of abnormal haemostasis in the ICU. Anaesthesia. 2015 Jan;70 Suppl 1:121-7, e40-1. doi: 10.1111/anae.12908. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Describe the Pattern of Homeostasis Disorders occur in Critical Care Unit in Assiut University Study the causes of either bleeding or thrombotic events in Critical care unit. Describe the pattern of the disease regarding age, sex and predisposing factors. Baseline
Secondary Correlate Supportive and Definitive Treatment and Outcomes of Patients with Homeostasis Disorder in ICU. Study the forms of transfusion ( e.g.packed red blood cells, Platelet , Fresh frozen plasma), anti bleeding measures (e.g. Tranexamic acid), anticoagulant and anti platelet drugs received by the patients and their outcomes Baseline
See also
  Status Clinical Trial Phase
Recruiting NCT05775731 - Markers of Inflammation and of the Pro-thrombotic State in Hospital Shift and Day Workers
Recruiting NCT04600609 - Examining the Experiences of Children With Blood Disorders
Active, not recruiting NCT04309084 - Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma Phase 1
Completed NCT04757285 - Copeptin and Psychological Stress of Medic During COVID-19 Pandemic
Terminated NCT04729946 - Clinical and Urgent Colonoscopy Outcomes Using the Pure-Vu® Cleansing System N/A
Not yet recruiting NCT06242353 - Coagulopathy in Childhood Acute Lymphoblastic Leukaemia
Completed NCT04499612 - Influence of Cardiac Implantable Electronic Devices on the Hemostatic System
Not yet recruiting NCT06328647 - Quantra Point-of-Care Hemostasis Monitoring N/A
Recruiting NCT04650529 - Gyeongsang National University Hospital Registry
Completed NCT03756948 - Viscoelastic Tests-Guided Therapy In Liver Transplantation N/A
Recruiting NCT05476458 - To Evaluate Efficacy of Red Dichromatic Imaging (RDI) in Achieving Hemostasis During POEM Using GF 1500 UGI Scope
Recruiting NCT04762576 - Thrombin in Cardiac Surgery
Completed NCT03555383 - Individualized Multimodal Hemostasis Evaluation Pyramid (IMHOTEP)
Terminated NCT03806556 - A Pediatric Trial Using Tranexamic Acid in Thrombocytopenia Phase 1/Phase 2
Recruiting NCT03281252 - A Prospective Study of Evaluation of Minor Bleeding and Utility of Bleeding Criteria in Acute-on-chronic Liver Failure Patients in China N/A